Delcath Systems, Inc. (NASDAQ: DCTH), a cutting-edge pharmaceutical and medical device company dedicated to combating primary and metastatic liver cancers, has announced a successful funding round, raising $16.3 million. This capital injection is pivotal as Delcath enhances its clinical and commercial initiatives surrounding its proprietary product, Melphalan Hydrochloride for Injection, utilized with the innovative Delcath Hepatic Delivery System (Melphalan/HDS). This system is specifically designed to administer high-dose chemotherapy directly to the liver, minimizing systemic exposure—an advancement crucial for patients battling these devastating conditions.
Currently in late-stage clinical development in the United States, Delcath has commenced initial commercial activities across Europe, where the Melphalan/HDS is marketed under the trade name Delcath Hepatic CHEMOSAT® Delivery System for Melphalan (CHEMOSAT). With over 250 successful CHEMOSAT treatments performed at more than 20 prestigious cancer centers in Europe, the focus now lies on expanding clinical adoption and leveraging physician insights to secure favorable reimbursements. The recent funds will facilitate our ongoing FOCUS Pivotal Study in Hepatic Dominant Ocular Melanoma and support the exploration of orphan indications in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. As we continue to position Melphalan/HDS as a vital option for stand-alone or complementary therapy for liver cancer, this funding represents a significant step toward improving treatment outcomes and offering hope to patients worldwide.
